Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer

Prostate

Volumn 72, Issue 12, 2012, Pages 1295-1305

  Locke, Jennifer A ^a,b   Zafarana, Gaetano ^a,b   Malloff, Chad A ^c   Lam, Wan L ^c   Sykes, Jenna ^a,b   Pintilie, Melania ^a,b   Ramnarine, Varune Rohan ^a,b   Meng, Alice ^a,b   Ahmed, Omer ^a,b   Jurisica, Igor ^a,b   Guns, Emma Tomlinson ^d   Van Der Kwast, Theo ^a,b   Milosevic, Michael ^a,b   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

aCGH; androgen synthesis; diagnostic biopsies; Gleason score; HSD17B2; prostate cancer; radiotherapy; StAR

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ALLELE; ANDROGEN SYNTHESIS; ARTICLE; CANCER PATIENT; CANCER RELAPSE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA DETERMINATION; GENE; GENE LOCUS; GENETIC STABILITY; GENOME; GLEASON SCORE; HORMONE RESPONSE; HSD17B2 GENE; HUMAN; HUMAN TISSUE; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; STAR GENE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGENS; COHORT STUDIES; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864287911     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22478     Document Type: Article

References (28)

1. Korets R, Motamedinia P, Yeshchina O, Desai M, McKiernan JM,. Accuracy of the Kattan nomogram across prostate cancer risk-groups. BJU Int 2011; 108: 56-60.
2. Nichol AM, Warde P, Bristow RG,. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues. Cancer 2005; 104: 891-905. (Pubitemid 41170215)
3. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292 (7): 821-827. (Pubitemid 39079668)
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
5. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase1-2 study. Lancet 2010; 375: 1437-1446.
6. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M,. An overview on 5alpha-reductase inhibitors. Steroids 2010; 75: 109-153.
7. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N,. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 2010; 151: 3514-3520.
8. Poirier D,. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anticancer Agents Med Chem 2009; 9: 642-660.
9. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG,. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009; 69: 1091-1100.
10. Shah SP, Xuan X, DeLeeuw RJ, Khojasteh M, Lam WL, Ng R, Murphy KP,. Integrating copy number polymorphisms into array CGH analysis using a robust HMM. Bioinformatics 2006; 22: e431-e439. (Pubitemid 44288313)
11. Chi B, deLeeuw RJ, Coe BP, Ng RT, MacAulay C, Lam WL,. MD-SeeGH: A platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics 2008; 9: 243.
12. Chi B, DeLeeuw RJ, Coe BP, MacAulay C, Lam WL,. SeeGH-A software tool for visualization of whole genome array comparative genomic hybridization data. BMC Bioinformatics 2004; 5: 13.
13. Roach M III, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW,. Defining high risk prostate cancer with risk groups and nomograms: Implications for designing clinical trials. J Urol 2006; 176: S16-S20. (Pubitemid 44754980)
14. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
15. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-6415.
16. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
17. Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns ES,. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009; 115: 126-136.
18. Dillard PR, Lin MF, Khan SA,. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295: 115-120.
19. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
20. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108: 13728-13733.
21. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y,. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313.
22. Qiu W, Zhou M, Mazumdar M, Azzi A, Ghanmi D, Luu-The V, Labrie F, Lin SX,. Structure-based inhibitor design for an enzyme that binds different steroids: A potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem 2007; 282: 8368-8379. (Pubitemid 47093565)
23. Auchus RJ,. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15: 432-438. (Pubitemid 39440726)
24. Rove KO, Crawford ED,. Dutasteride: Novel milestones in prostate cancer chemoprevention. Drugs Today (Barc) 2011; 47: 135-144.
25. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU,. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504.
26. Abd-Elaziz M, Moriya T, Akahira J, Suzuki T, Sasano H,. StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: Immunohistochemical and real-time PCR studies. Cancer Sci 2005; 96: 232-239. (Pubitemid 40767061)
27. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr., The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2003; 98: 2344-2350. (Pubitemid 37466649)
28. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS,. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-565.